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mTORC1 and mTORC2 
Differentially Regulate Cell 
Fate Programs to Coordinate 
Osteoblastic Differentiation in 
Mesenchymal Stromal Cells
Theres Schaub1,2,3, Dennis Gürgen1,4,5, Deborah Maus1,6, Claudia Lange7, Victor Tarabykin3, 
Duska Dragun1,4,8* & Björn Hegner1,4,8,9
Vascular regeneration depends on intact function of progenitors of vascular smooth muscle cells such 
as pericytes and their circulating counterparts, mesenchymal stromal cells (MSC). Deregulated MSC 
differentiation and maladaptive cell fate programs associated with age and metabolic diseases may 
exacerbate arteriosclerosis due to excessive transformation to osteoblast-like calcifying cells. Targeting 
mTOR, a central controller of differentiation and cell fates, could offer novel therapeutic perspectives. 
In a cell culture model for osteoblastic differentiation of pluripotent human MSC we found distinct 
roles for mTORC1 and mTORC2 in the regulation of differentiation towards calcifying osteoblasts 
via cell fate programs in a temporally-controlled sequence. Activation of mTORC1 with induction of 
cellular senescence and apoptosis were hallmarks of transition to a calcifying phenotype. Inhibition of 
mTORC1 with Rapamycin elicited reciprocal activation of mTORC2, enhanced autophagy and recruited 
anti-apoptotic signals, conferring protection from calcification. Pharmacologic and genetic negative 
interference with mTORC2 function or autophagy both abolished regenerative programs but induced 
cellular senescence, apoptosis, and calcification. Overexpression of the mTORC2 constituent rictor 
revealed that enhanced mTORC2 signaling without altered mTORC1 function was sufficient to inhibit 
calcification. Studies in mice reproduced the in vitro effects of mTOR modulation with Rapamycin on 
cell fates in vascular cells in vivo. Amplification of mTORC2 signaling promotes protective cell fates 
including autophagy to counteract osteoblast differentiation and calcification of MSC, representing 
a novel mTORC2 function. Regenerative approaches aimed at modulating mTOR network activation 
patterns hold promise for delaying age-related vascular diseases and treatment of accelerated 
arteriosclerosis in chronic metabolic conditions.
Vascular regeneration depends on local vascular smooth muscle cell (VSMC) precursor cells, or pericytes1–3, that 
are replenished by mesenchymal stromal cells (MSC)4. MSC are progenitor cells featuring multi-lineage differen-
tiation potential including VSMC5,6 and osteoblast phenotypes in combination with high regenerative capacity for 
the vasculature7 and other organs. In bone, MSC can top up the osteoblast pool, thereby increasing bone density 
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and fracture resistance8. Both compartments, bone and vasculature, are in close interaction, reciprocally regu-
lated via cellular, endocrine, and metabolic signals9. During aging, they progressively lose their adaptability and 
regenerative capacity on cellular and systemic levels10,11. Consequently, deregulated cellular differentiation pro-
cesses lead to calcium loss from bones and increased calcium deposition in blood vessels. Clinical correlates are 
osteoporosis and arteriosclerosis12,13. Chronic metabolic disease conditions such as diabetes mellitus or chronic 
kidney disease with uremia accelerate both detrimental clinical phenotypes14. This involves mechanisms usually 
associated with age, such as premature cellular senescence and other cell fates15 adversely affecting viability, adap-
tibility, and resistance to stress10,11,16.
Arterial calcification has been attributed to active transformation of VSMC to osteoblast-like cells reminiscent 
of intramembranous and enchondral bone formation17,18. However, cells with an MSC phenotype found in the 
arterial adventitia have been shown to be a major source of osteoblast-like cells in intimal and medial calcification 
in a mouse model of chronic kidney disease19. The uremic millieu triggers osteoblastic differentiation of MSC and 
calcification20, implying loss of vascular progenitor properties. Hence, preservation and restoration of physiologic 
MSC function for endogenous regeneration can be considered more effective than targeting terminally differen-
tiated cells such as VSMC and osteoblast-like cells to counteract or even reverse accelerated vascular calcification 
in patients with pro-arteriosclerotic conditions.
The atypical serine/threonine kinase mechanistic target of Rapamycin (mTOR) orchestrates cellular func-
tions in response to metabolic cues and growth factors21. It is contained in two structurally and functionally 
distinct multi-protein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Activation 
of both complexes facilitates cell growth and survival21,22. The major function of the mTORC1 down-stream 
targets p70-S6 kinase, 4E-BP1 and others is promotion of cellular growth and proliferation via increased protein 
and lipid synthesis23 and inhibition of autophagy24 at the cost of premature cellular senescence25. Functions of 
mTORC2 are less well studied and include organization of the actin cytoskeleton26, control of ion transport27, and 
anti-apoptotic properties via stimulation of the AKT-FOXO pathway28. Direct involvement of specific branches 
of the mTOR signaling network in regulation of mammalian life-span29, cellular senescence25,30, and vascu-
lar smooth muscle and osteoblast differentiation5,6,31,32 opens a perspective for therapeutic mTOR targeting in 
aging-related pathologies of the bone-vascular axis. The macrolide Rapamycin (Rapa) is a complex modulator 
of mTOR signaling since it effectively blocks most but not all mTORC1 functions21 without inhibitory effects on 
mTORC2, aside from a few exceptions33. Rapa and its derivatives, the “rapalogs”, are increasingly used in clinical 
applications ranging from local release in vessels from drug-eluting stents to systemic therapy of cancer, immuno-
logic and genetic diseases as well as immunosuppression after organ transplantation. In animal models, Rapa has 
been shown to counteract degenerative and age-related pathologies in heart and brain34,35, making it a prototypic 
candidate to stimulate endogenous regenerative processes.
We tested the hypothesis that during osteoblastic transformation of MSC, mTORC1 and mTORC2 orchestrate 
cell-fate programs in a chronologically coordinated manner resulting in osteoblast differentiation and calcifica-
tion. In addition, we provide evidence from in vitro and in vivo studies that enhanced mTORC2 function was both 
indispensable and sufficient to establish a regenerative cell fate pattern conferring protection from calcification to 
MSC in vitro. Selective induction of protective cell fate programs via therapeutic manipulation of mTOR network 
components holds promise to preserve and restore a regenerative MSC phenotype capable of rejuvenating the 
bone-vascular axis in age-related pathologies and to protect from accelerated vascular calcification caused by 
metabolic diseases.
Materials and Methods
All experiments were performed in accordance with relevant guidelines and regulations. The isolation of 
MSC was approved by the Ethik-Kommission der Ärztekammer Hamburg (#2572) and the Ethikkommission 
Ethikausschuss 4, CBF, Charité (#EA4/114/11). The study was conducted in accordance with the Declaration of 
Helsinki and was approved by local ethic authorities. All subjects provided written informed consent. The exper-
iments were conducted according to institutional guidelines (“Gute Wissenschaftliche Praxis”, Charité University 
Hospital). All animal experiments were approved by local authorities (LaGeSo G0028/11, Berlin, Germany) and 
were conducted according to institutional animal care guidelines (Charité University Hospital).
Isolation and culture of MSC. MSC were isolated from bone marrow aspirates obtained from 20 healthy bone 
marrow donors (7 female, 13 male), median age 31 years (range 0.5–42) following a previously described protocol36. 
In brief, bone marrow mononuclear cells were purified by Ficoll density gradient centrifugation. Plastic adherent 
cells were expanded in α-MEM (#E15-862, PAA) supplemented with penicillin/streptomycin (Gibco), 2 IU/ml hep-
arin (Ratiopharm), and 5% platelet lysate at 37 °C and 5% CO2. Cells were used up to passage 5.
Characterization of MSC. All preparations were assessed for surface marker expression, chondroblastic, 
adipocytic and osteoblastic differentiation capacity as well as expression of VSMC marker proteins. Three cell 
preparations were exemplarily studied for functional L-type calcium channels as described below.
50,000 cells were labeled with 3 µl antibody or corresponding isotype control and analyzed using a Beckton 
Dickinson FACS Calibur. CD73 (BD, #561254), CD90 (Miltenyi, #130-095-403), CD105 (BD, #561443), CD11b 
(Miltenyi, #130-081-201), CD14 (BD, #557153), CD19 (Miltenyi, #130-091-328), CD34 (Miltenyi, #130-092-213), 
CD45 (BD, #555492), HLA-DR (BD, #559866), with the corresponding isotype controls IgG2a (BD, #553456), 
isotype IgG2aκ (BD #555573), and isotype IgG1 (Miltenyi, #130-081-002), were used.
Chondroblastic differentiation was tested in pellet cultures with 1 × 106 cells in 4 ml DMEM contain-
ing 1 mM sodium pyruvate (Applichem), 20 mM HEPES (Roth) pH 7.3, 0.1 µM dexamethasone, 0.1 mM 
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2-phospho-L-ascorbic acid, and 10 ng/ml TGF-β1 (R&D). After 4 weeks, protein extraction and western blot 
analysis were performed.
To induce adipogenesis, confluent monolayers were treated with DMEM containing 1 μM dexametha-
sone, 0.01 mg/ml insulin (Berlin-Chemie), 0.2 mM indomethacin (Cayman Chemical Company), and 0.5 mM 
3-isobutyl-1-methyl-xanthine (Serva) for 4 weeks. After fixation with 4% paraformaldehyde, staining was per-
formed with 6 ml of 0.5% Oil red O (Sigma) in isopropanol added to 4 ml deionized water.
For osteoblastic differentiation, 13,000 MSC/cm² were incubated with osteoblast induction medium (OM) 
consisting of Dulbecco’s Modified Eagle’s Medium (DMEM; PAA) supplemented with 2 mM glutamine (Lonza), 
penicillin/streptomycin (Gibco), 1% FCS (Lonza), 10 mM β-glycerophosphate (Applichem), 500 µM ascorbic 
acid, and 100 nM dexamethasone (both from Sigma) for 3 weeks. After fixation with ice-cold methanol, cells were 
stained with filtered 5% Alizarin (1,2-dihydroxyanthraquinone, Sigma) pH 4. After several wash steps with PBS 
pH 6.0, wells were dried.
Photomicrographs were taken on a Zeiss Axiovert 40 CFL using a Canon PowerShot A649.
L-Type Ca2+ channel imaging. In six-well-plates, 75,000 cells per well were seeded onto glass coverslips 
in complete α-MEM and allowed to adhere overnight. Medium was switched to phenol red free DMEM without 
FCS or platelet lysate for 24 h. Cells were loaded with the Ca2+ indicator fluo-4-AM (Invitrogen, Karlsruhe, 
Germany) (10 μM) and pluronic acid (Merck, Darmstadt, Germany) (0.01%; w/v) for 30 min at room temper-
ature in PSS (NaCl 134 mM, KCl 6 mM, CaCl2 2 mM, MgCl2 1 mM, HEPES 10 mM, glucose 10 mM, pH 7.4 
with NaOH). Before taking records, the cells were washed with PSS and further incubated for 20 min to allow 
de-esterification of the dye.
Pretreatment with 1 μmol/L nimodipine (Sigma-Aldrich) was carried out for 5 minutes before adding KCl. 
Fluo-4 loaded cells were imaged using a BioRad MRC 1024 laser scanning confocal microscope attached to a 
Nikon Diaphot 300 inverted microscope. Excitation was performed at 488 nm and the emission wavelength was 
500 nm. Images were collected at a rate of 1/second. Image processing was done using imageJ 1.41i (National 
Institutes of Health, USA, http://rsbweb.nih.gov/ij/). Background fluorescence was subtracted and changes in 
intracellular calcium were expressed as relative fluorescence changes, i.e. F/Fo (with Fo indicating the fluores-
cence before stimulation and F the time-dependent fluorescence signal after stimulation). Peak amplitudes of 
Ca2+ transients were calculated as (Fpeak-Fo)/Fo. Stock solutions of fluo-4 AM (2.5 mM) and of nimodipine 
(1 mM) were made using DMSO as solvent. High external potassium solutions were made by iso-osmotic substi-
tution of NaCl with KCl in the PSS.
Drug treatments. According to the manufacturer’s instructions, the following stock solutions were pre-
pared with DMSO: Rapa (LC Laboratories) 20 µM, Bafilomycin A1 (Selleck) 10 µM, MK-2206 (Selleck) 100 µM. 
Aliquots were stored at −80 °C. Controls were treated with the equivalent volume of DMSO.
Immunocytochemistry. 13,000 MSC/cm² were seeded on Thermanox Plastic Coverslips (Nunc) in indi-
cated medium for 3 weeks. After fixation with methanol and blocking with 3% BSA/PBS, primary antibodies 
(Osteopontin, abcam, ab8448; Collagen I, abcam, ab34710; both 1:500 in blocking solution) were incubated for 2 
hours at 37 °C in a humid chamber. After washing with PBS, secondary antibody incubation (HRPO-conjugated 
IgG, Dianova) followed. Signal was developed with AEC High Sensitivity Substrate Chromogen (Dako) before 
extensive washing.
Western blot analysis. Western blot was performed following standard protocols. Blocking was done with 
10% BSA/TBS-T for 2 hours at room temperature. All antibodies were diluted in blocking solution as follows: 
SM22alpha (abcam, ab10135, 1:10 000), Calponin (Sigma, 1:10 000, C2687), MLCK (Sigma, 1:500, M7905), 
SMA (Sigma, 1:5000, M7905), Collagen IIA1 (Santa Cruz, scr-52658, 1:400), Osteopontin (abcam, ab8448, 
1:1,000), Cbfa1/Runx2 (MBL, D130-3, 1:500), Osterix (abcam, ab22552, 1:500), Collagen III (abcam, ab6310, 
1:500), pp70S6KThr389 (R&D, AF8963, 1:500), pp70S6KThr421/Ser424 (CST, #9204, 1:1,000), pAKTSer473 (CST, #4080, 
1:1,000) pAKTThr308 (CST, #2965, 1:1,000), ERK1/2Thr202/Tyr204 (CST, #9106, 1:1,000), LC3B (Novus, NB100-2220, 
1:1,000), p16INK4a (Santa Cruz, sc-468, 1:500), SQSTM1/p62 (#5114, CST, 1:1000), cleaved caspase 3 (CST, #9661, 
1:500), Bcl-2 (Santa Cruz, sc-492, 1:500), Rictor (CST, #9476, 1:1,000), mTOR (CST, #2972, 1:1000), Raptor (CST, 
#2280, 1:1000), AKT (CST, #9272 1:2000), p70-S6 (CST, #9202, 1:1000), ERK1/2 (CST, #9102, 1:1000), α-Tubulin 
(Sigma, T9026, 1:6000), GAPDH (hytest, 5G4, 1:100,000). After incubation with secondary antibodies (Dianova), 
SuperSignal West Chemiluminescent Substrate (Thermo Fisher) was used for visualization in a G:BOX F3 device 
(Syngene).
Alkaline phosphatase activity. Activity of alkaline phosphatase (ALP) was determined at day 7 after 
induction of osteoblast differentiation. Cells were lysed with 250 µl ALP lysis buffer (150 mM Tris pH 10.0 (Roth), 
0.1 mM ZnCl2, 0.1 mM MgCl2, 1% Triton-X100 (all from Applichem)) at room temperature under constant agita-
tion for 30 minutes. Supernatants were centrifuged for 10 min at 12,000 rpm and 4 °C. Each sample was measured 
in 4 replicates in a 96-well-plate with 50 µl per well mixed with 200 µl substrate solution (ALP buffer with freshly 
dissolved p-Nitrophenyl phosphate (Fluka) at 2.7 mM). Optical density (OD) at 405 nm was measured at baseline 
and every 5 min during the incubation time of 1 hour at 37 °C. ∆OD values to baseline ODs at one chosen time 
point during the linear phase were divided by the protein concentration of the sample determined with the DC 
Protein Assay (Bio-Rad).
Calcium deposition. Extracellular calcium deposition of differentiating MSC was assessed after 3 weeks of 
incubation with OM. Calcium was solubilized by shaking cells overnight in 200 µL 0.6 M HCl at 4 °C. Samples 
were centrifuged for 60 min at 20,000× g and 4 °C. 10 µL of either calcium standards or sample supernatant were 
4Scientific RepoRtS | (2019) 9:20071 | https://doi.org/10.1038/s41598-019-56237-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
mixed with 150 µL 0.1 mg/mL ortho-cresolphthalein complexone, 1 mg/mL 8-hydroxy-quinoline, 0.7 M HCl, 
and 150 µl 15% 2-amino-2-methyl-1-propanol in H2O, pH 10.7. OD was measured at 540 nm in duplicates. Blank 
absorption was subtracted and calcium concentrations were calculated using a standard curve. To analyze the 
protein content for normalization, 230 µl 0.1 M NaOH/0.1% SDS solution was added to the remainder of the 
sample and mixed for about 10 minutes. After centrifugation at 20,000× g for 10 min, 20 µl were used for protein 
quantification with the DC protein assay (Bio-Rad) in duplicates.
X-Gal staining. Senescence was visualized via hydrolysis of 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
by cellular β-galactosidase. MSC were seeded on glass slides in 12-well plates at 50,000 cells per well and incubated 
with indicated medium for 3 weeks. Cells were fixed in 2% paraformaldehyde/0.25% glutaraldehyde in PBS with 
1 mM MgCl2 pH 6.0. Staining was performed for 12 hours at 37 °C using 5 mM K3Fe(CN)6/5 mM K4Fe(CN)6 × 3H2O 
in PBS with 1 mM MgCl2 pH 6.0 freshly supplemented with 40 mg 5-Bromo-4-chloro-3-indolyl-β-D-galactoside/
ml and N,N-Dimethylformamide to a final concentration of 1 mM. Coverslips were washed and mounted on glass 
slides with AquaPolymount (Polyscience Inc) before micrographs were taken.
Apoptosis ELISA. Quantification of apoptosis was performed by measuring fragmented DNA with the Cell 
Death Detection ELISA PLUS Kit (Roche) following the manufacturer’s instructions. To normalize for protein 
content, total protein of lysates was quantified with the DC protein assay (Bio-Rad).
LDH activity. LDH analysis was performed with the Cytotoxicity Detection Kit (Roche) following the man-
ufacturer’s instructions. To normalize for protein content, 500 µl cell culture supernatant were mixed with 250 µl 
20% trichloric acid, incubated on ice for 30 min, and centrifuged for 30 min at 4 °C with 20,000× g. The pellet was 
washed twice with ice-cold acetone. After drying, the pellet was resolved in protein lysis buffer (100 mM Tris pH 
8,0; 0.2% SDS; 1% Triton X-100), and total protein was quantified with the DC protein assay (Bio-Rad).
Cloning and lentivirus production. For rictor knockdown, pSuperRetroPuroshRNA-Rictor and pLVTH 
were digested with EcoRI/ClaI and the shRNA-fragment was ligated into the pLVTH-backbone. For flag-rictor 
over-expression, the pLJM1 vector-backbone was used. After confirmation of plasmid accuracy, lentiviral parti-
cles were produced with a second generation packaging system in 293T cells via calcium phosphate-transfection. 
Virus-production medium containing 10% FCS and 1.2% BSA was collected 24 and 48 hours later. After straining 
through 0.45 µm filters and concentrating via ultracentrifugation (2 hours at 100,000× g), virus was supple-
mented with protamine sulfate (final concentration 10 µg/ml) before MSC were transduced at low cell density. 
Efficiency was confirmed by GFP expression.
Animals. All experiments were approved by local authorities (LaGeSo G0028/11, Berlin, Germany) and 
were conducted according to institutional animal care guidelines (Charité University Hospital). As previously 
described37, male ten-week-old mice (C57BL/6JRccHsd, Harlan Winkelmann) were exposed to Rapa (1.5 mg/
kg) or vehicle, both administered intraperitoneally every third day over a period of 37 days. Rapa was dissolved 
in DMSO and diluted 1:1000 in a mixture of medium chain triglycerides (MCT; Miglyol 812, Caesar & Lorentz). 
Vehicle consisted of DMSO diluted 1:1000 in MCT. The administered volume was 5 mL/kg resulting in 0.1–
0.15 mL per injection depending on the individual body weight of the mice. Aortas were excised, snap frozen in 
liquid nitrogen, and stored at −80 °C until analysis. 4 mice per group were studied.
Immunofluorescence histology. Cryosections of 6 µm were prepared using Tissue-Tek ® O.C.T™ 
Compound (Sakura) and a CM1900 Leica Cryostat. After fixation, slides were blocked for 4 hours with 5% rabbit 
serum (Invitrogen). Primary antibodies were incubated for 12 hours as follows: pAKTSer473 (CST, #4080, 1:200), 
and pp70-S6Thr389 (Santa Cruz, sc-11759, 1:100) in 3% rabbit serum-PBS. Bcl-2 (Santa Cruz, sc-492, 1:250), 
p16INK4a (Santa Cruz, sc-468, 1:250), caspase 3 (Santa Cruz, sc-7148, 1:250), and LC3B (Novus, NB100-2220, 
1:250) in 3% rabbit serum-TBS-T with 0.1% Triton-X100 (Applichem). Anti-rabbit and anti-goat Alexa Fluor 586 
secondary antibodies (Invitrogen, 1:2000) were applied in TBS-T with 1% goat serum for 2 hours at room temper-
ature. Micrographs were taken using an Axiacam HR camera device on an Axio Imager A1 immunofluorescence 
microscope (Zeiss). For quantification, 100 DAPI stained nuclei were counted and the proportion of antibody 
positive cells was determined.
Statistics. All data are expressed as mean +/− SEM and were analyzed with 1-way or 2-way ANOVA fol-
lowed by post-testing with Bonferroni’s test for multiple comparisons as appropriate. All analyses were performed 
with GraphPad Prism version 5.02 for Windows (GraphPad Software, San Diego California USA). Significance 
was considered at a value of p < 0.05.
Results
Cell culture model for osteoblastic differentiation of MSC. To study mTOR-dependent cell fate pro-
grams during osteoblastic differentiation in progenitor cells, a cell culture model using human bone marrow-de-
rived MSC with characteristic cell surface marker profile and multilineage differentiation capacity as defined by 
the International Society for Cellular Therapy38 was established (Fig. 1A–D). In addition, MSC displayed features 
of vascular smooth muscle cells (VSMC) as previously reported5,6,39. MSC expressed the smooth muscle marker 
proteins SM22α, smooth muscle calponin (sm-Calponin), myosin light chain kinase (MLCK) and smooth mus-
cle-α-actin (SMA) (Fig. 1E). Moreover, they featured functional voltage-dependent dihydropyridine-sensitive 
(Cav1.2) L-type calcium channels characteristic for VSMC (Fig. 1F).
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Phenotype conversion was induced by incubation with osteoblast induction medium (OM) containing high 
phosphate concentrations for 21 days. MSC derived osteoblast-like cells expressed the osteoblast marker proteins 
osteopontin, collagen I, Cbfa1, osterix, and collagen III (Fig. 2A–F) and displayed high levels of alkaline phos-
phatase (ALP) activity (Fig. 2G). On a functional level, differentiated cells extensively produced calcified extracel-
lular matrix (Fig. 2A,H). MSC from male donors developed slightly higher ALP activity than MSC from female 
donors after osteoblastic differentiation (Fig. 2G) while calcium deposition did not differ significantly (Fig. 2H).
The mTOR network controls osteoblastic differentiation of MSC. The involvement of mTOR sig-
naling in osteoblastic phenotype conversion was tested with the mTOR inhibitor Rapa. Cells co-incubated with 
Rapa throughout the whole differentiation period of 21 days expressed lower levels of osteoblast marker proteins 
(Fig. 2A–F), and displayed strongly reduced ALP activity after 7 days (Fig. 2G) and calcium deposition after 21 
Figure 1. Cell culture model for osteoblastic differentiation of pluripotent human bone marrow-derived 
MSC. (A) Representative FACS analysis out of 20 of an MSC defining surface marker panel confirming 
homogeneity of isolated cells. More than 98% of cells are positive for CD73, CD90 and CD105 and negative 
for CD11b, CD14, CD19, CD34, CD45, and HLA-DR compared to isotype control (grey). (B) Chondroblastic 
differentiation of MSC after incubation for 32 days with chondroblast induction medium demonstrated by 
western blot analysis for chondrocyte-specific type II collagen. Two representative cell preparations out of 20 
are shown. α-Tubulin served as loading control. (C) Adipocytic differentiation of MSC after incubation for 
21 days with adipocyte induction medium demonstrated by staining of intracellular lipid droplets with Oil 
red O. Representative experiment out of 20, phase contrast microscopy, original magnification × 200, scale 
bar = 50 µm. (D) Osteoblastic differentiation of MSC after incubation for 21 days with osteoblast induction 
medium demonstrated by staining of extracellular hydroxyapatite deposits with Alizarin red S. Representative 
experiment out of 20, phase contrast microscopy, original magnification x100, scale bar = 50 µm. (E) Baseline 
expression of vascular smooth muscle marker proteins in MSC: SM22α, smooth muscle calponin (sm-
Calponin), myosin light chain kinase (MLCK), smooth muscle-α-actin (SMA). Western blot analyses of 
three representative cell preparations out of 20 are shown. α-Tubulin served as loading control. (F) Calcium 
transients without (control) and after pretreatment with nimodipine (Nimodipine) in MSC at base line 
showing expression of functional voltage-dependent dihydropyridine-sensitive (Cav1.2) L-type Ca2+ channels. 
Representative experiment out of three; 20–30 individual cells were studied for each tracing.
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Figure 2. Modulation of MSC osteoblastic differentiation by Rapa. MSC were cultured under control 
conditions (no OM) or with osteoblast induction medium in presence of vehicle (OM) or 20 nM Rapa 
(OM+Rapa). (A) Immunocytochemistry for osteoblast marker proteins and Alizarin red S staining of 
calcium deposits after 21 days. Osteopontin (OP), collagen I (Coll I). Representative experiment out of 20, 
phase contrast microscopy, original magnification × 200, scale bar  =  100 µm. (B–F) Western blot analysis of 
osteoblast marker proteins. MSC were cultured for 21 days under control conditions (no OM) or with osteoblast 
induction medium in the presence of vehicle (OM) or 20 nM Rapa (OM+Rapa). Representative western blots 
(B) and densitometric quantifications (C–F) are shown. Numbers of independent experiments are indicated at 
the bottom of each graph. Band intensities were normalized to α-tubulin as a loading control. Control (no OM) 
was set to 1. Bars represent mean + SEM, *P < 0.05, **P < 0.01, ***P < 0.001. (G) Alkaline phosphatase (ALP) 
activity was measured after 7 days of incubation and normalized to total protein concentrations of lysates. Cells 
from 9 male and 7 female individuals were analyzed. (H) Calcium deposition was quantified after incubation 
for 21 days and normalized to total protein concentrations. Cells from 9 male and 7 female individuals were 
analyzed.
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days (Fig. 2H), indicating a central role for mTOR in osteoblastic differentiation of MSC. There was no interaction 
between sex and the response to treatment (Fig. 2G,H).
As part of a detailed analysis of the mTOR network, activation of the two distinct signaling branches, 
mTORC1 and mTORC2, was analyzed in osteoblasts derived from MSC in comparison to undifferentiated MSC. 
MSC-osteoblasts differentiated for 21 days displayed about 50% higher phosphorylation levels of p70-S6 kinase 
at threonine 389 (p70-S6K; Fig. 3A), a direct downstream target of mTORC1 (Fig. 3I,J). Phosphorylation of AKT 
at serine 473, downstream of mTORC2 (Fig. 3I,J), was increased 3-fold (Fig. 3B). Interestingly, Rapa intervention 
potently reduced mTORC1-dependent p70-S6K phosphorylation in MSC-osteoblasts (Fig. 3A), while mTORC2 
activity was tremendously upregulated (Fig. 3B). Expression levels of raptor and rictor, the two key proteins 
forming mTORC1 (raptor) and mTORC2 (rictor) in association with mTOR were not changed upon treatment 
with OM alone or with OM and Rapa (Fig. 3C,D). Levels of mTOR increased slightly when MSC where treated 
with OM and Rapa (Fig. 3E). Investigation of upstream modulators and feedback loops of mTOR complexes 
revealed activation of phosphatidyl inositol-3 phosphate kinase (PI3K) signaling in MSC-derived osteoblasts as 
evidenced by phosphorylation of AKT at threonine 308 (Fig. 3F). Rapa treatment further enhanced PI3K activity 
(Fig. 3F). Extracellular regulated kinase 1/2 (ERK1/2) and the ERK-dependent phosphorylation site of p70-S6K 
(pp70-S6KThr421/Ser424) did not show altered phosphorylation after 3 weeks of OM stimulation without or with 
Rapa (Fig. 3G,H). These findings indicate that the osteoblastic phenotype of MSC is associated with signaling 
via PI3K and its downstream targets mTORC1 and mTORC2 (Fig. 3I). Rapa-mediated prevention of osteoblas-
tic transformation and calcification is related to inhibition of mTORC1 with simultaneous mTORC2 activation 
(Fig. 3J). The stimulation of mTORC2 by Rapa can be explained by release of direct inhibitory signals from 
mTORC1 on mTORC2 and on PI3K (Fig. 3I,J)40.
Degenerative cell fates are activated during osteoblastic differentiation of MSC in a temporally 
coordinated manner. To establish a mechanistic link between signal and phenotype, cell fate programs 
related to mTORC1 (autophagy, cellular senescence) and mTORC2 (apoptosis) were studied. The autophagosome 
constituent LC3B II was more abundant in MSC differentiated into osteoblasts by exposure to OM over 3 weeks 
(Fig. 4A). In addition, p62, a substrate of autophagosomal degradation, accumulated simultaneously (Fig. 4B). 
This suggests reduced autophagic flux with less degradation of autophagosomal proteins due to inhibition of 
autophagy. Osteoblasts also featured high expression levels of p16INK4a (Fig. 4C) and β-galactosidase (Fig. 4D), 
both indicators of cellular senescence. Increased levels of cleaved caspase 3, fragmented DNA, and LDH released 
into the supernatant (Fig. 4E–G) in parallel with unaffected levels of the anti-apoptotic protein Bcl-2 (Fig. 4H) 
indicated apoptotic cell death. MSC that were treated with Rapa during exposure to OM differed markedly in 
their cell fate responses: Autophagic flux appeared to be enhanced, as amounts of LC3B II and p62 decreased as 
compared to OM treatment (Fig. 4A,B). Rapa conferred resistance to induction of cellular senescence as indicated 
by reduced p16INK4a and β-galactosidase (Fig. 4C,D), and apoptosis was prevented as shown by reduced cleaved 
caspase 3, less fragmented DNA, lower LDH activity in supernatants, and increased Bcl-2 (Fig. 4E–H).
Temporal relations of signaling events, cell fates, and phenotypic changes were deciphered by following 
MSC undergoing osteoblastic differentiation over a time course of 3 weeks. The earliest events were activation 
of mTORC1 and mTORC2 detectable on day 3 continuing until the end of the study (Fig. 5A). LC3B II and p62 
increased from day 3 onward as an indication of reduced autophagic flux (Fig. 5A). Induction of cellular senes-
cence detected by p16INK4a was first evident on day 9 (Fig. 5A). At the same time, LDH activity in the supernatant 
started to rise as a sign of cell death (Fig. 5D). Phenotypically, ALP activity, an early marker of osteoblastic cell 
specificity, rose from day 3 to day 15 and declined thereafter (Fig. 5E). Calcium deposition was first noted on day 
6 and further accumulated from day 9 until the end of the study (Fig. 5F). This sequence suggests that signaling 
via mTORC1 and mTORC2 initiates osteoblastic differentiation indicated by ALP expression. Reduced autophagy 
precedes cellular senescence and cell death with calcification being the ultimate consequence of these events. ALP 
activity declines as cells progressively calcify or die.
When Rapa was added, activity of mTORC1 was suppressed far below baseline levels (Fig. 5B) while activa-
tion of mTORC2 was prominently increased (Fig. 5B). Accumulation of LC3B II and p62 as well as expression of 
p16INK4a were almost completely prevented (Fig. 5B). LDH activity showed a delayed (between days 12 and 15) 
and weak increase (Fig. 5D). ALP activity levels were lower overall (Fig. 5E) while calcium deposition started later 
(day 12) and was less pronounced (Fig. 5F). This indicates that intervention with Rapa modifies mTOR signaling 
and potently prevents induction of degenerative cell fates and calcification.
Blockade of autophagy exacerbates calcification of differentiated MSC. A pharmacologic inhib-
itor of autophagosomal acidification and degradation, bafilomycin A1, was continuously applied at a low dose 
(1 nM) to MSC undergoing osteoblastic differentiation in the presence of Rapa to exclude that lower levels of 
LC3B II in Rapa-treated MSC were due to reduced formation of autophagosomes instead of enhanced autophagic 
flux. With bafilomycin A1, LC3B II accumulated over time starting as early as day 3 (Fig. 5C), confirming persis-
tent formation of autophagosomes. Levels of p62 increased in parallel as an indication of reduced autophagoso-
mal activity (Fig. 5C). Inhibition of autophagy with bafilomycin A1 profoundly influenced cell fates while mTOR 
signaling was unaffected (Fig. 5C). Cellular senescence (p16INK4a) was greatly induced, even at the earliest time 
points (Fig. 5C). LDH activity indicating cell death increased with a steeper slope from day 3 until the end of the 
study (Fig. 5D). With regard to osteoblastic differentiation, ALP enzymatic activity was elevated throughout the 
whole time course (Fig. 5E). More calcium was deposited from day 3 to day 9 and a remarkably sharp increase 
started on day 12 resulting in excessive calcium deposition on day 21 (Fig. 5F).
Inhibition of AKT signaling or genetic depletion of mTORC2 abrogate the protective effect of 
Rapa on MSC calcification. We hypothesized that, in addition to activation of autophagy, prevention of 
8Scientific RepoRtS | (2019) 9:20071 | https://doi.org/10.1038/s41598-019-56237-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
Figure 3. Western blot analysis of the mTOR network during osteoblastic differentiation of MSC. Cells were 
cultured for 21 days under control conditions (no OM) or with osteoblast induction medium in presence of 
vehicle (OM) or 20 nM Rapa (OM+Rapa). (A) Phosphorylation of p70-S6 kinase at threonine 389 (pp70-
S6K389) for activation of mTORC1. (B) Phosphorylation of AKT at serine 473 (pAKT473) for activation of 
mTORC2. (C) Raptor as the key subunit of mTORC1. (D) Rictor as the key subunit of mTORC2. (E) mTOR as 
the serine/threonine kinase component of mTORC1 and mTORC2. (F) Phosphorylation of AKT at threonine 
308 (pAKT308) as an upstream modulator and part of a feedback loop involving phosphatidyl inositol-3 
phosphate kinase (PI3K). (G) Phosphorylation of ERK1/2 at threonine 202/tyrosine 204 (pERK202/204), and 
(H) its downstream target p70-S6 kinase at threonine 421/serine 424 (pp70-S6K421/424) as a side branch of 
p70-S6K activation. Densitometric quantifications and representative western blots are shown. Numbers 
of independent experiments are indicated at the bottom of each graph. Band intensities were normalized to 
GAPDH as a loading control. Control (no OM) was set to 1. Bars represent mean + SEM, *P < 0.05, **P < 0.01, 
***P < 0.001. (I) Scheme of the mTOR network without, and (J) with modulation by Rapa.
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apoptosis is a major mechanism by which Rapa exerts its anti-calcifying effects, since apoptotic bodies have been 
shown to function as a nidus for incipient calcification processes in VSMC41. We employed the pharmacologic 
AKT inhibitor MK-2206 to block Rapa-enhanced anti-apoptotic signaling via mTORC2/AKT in MSC undergo-
ing osteoblast differentiation. Addition of MK-2206 neutralized amplification of mTORC2-dependent AKTSer473 
phosphorylation when mTOR signaling was modulated by Rapa (Fig. 6A). As in the previous experiments, Rapa 
stimulated autophagic flux as indicated by reduced LC3B II and p62 (Fig. 6A), prevented the induction of cellular 
Figure 4. Degenerative cell fates are activated during osteoblast differentiation of MSC. Cells were cultured 
for 21 days under control conditions (no OM) or with osteoblast induction medium in presence of vehicle 
(OM) or 20 nM Rapa (OM+Rapa). (A) Western blot analysis of LC3B II and (B) of p62 for autophagic flux 
with higher levels indicating less degradation due to reduced autophagic flux. (C) Western blot analysis of 
p16INK4a indicating cellular senescence. (D) X-Gal staining for assessment of β-galactosidase a marker of cellular 
senescence. Representative experiment out of five, phase contrast microscopy, original magnification x400, 
scale bar = 100 µm. (D) Western blot analysis of cleaved caspase 3 to test for apoptosis. (E) ELISA measuring 
fragmented DNA normalized to total protein concentrations to quantify apoptosis. (F) Lactate dehydrogenase 
(LDH) activity in cell culture supernatants normalized to total protein concentrations for quantification of cell 
death. (G) Western blot analysis of the anti-apoptotic protein Bcl-2. Numbers of independent experiments 
are indicated at the bottom of each graph. For all western blot analyses representative blots are shown. For 
densitometric quantification, band intensities were normalized to GAPDH as a loading control. Control (no 
OM) was set to 1. Bars represent mean + SEM, **P < 0.01, ***P < 0.001.
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senescence (p16INK4a, Fig. 6A), enhanced anti-apoptotic mechanisms (Bcl-2, Fig. 6A), and decreased apoptosis as 
shown by reduced cleaved caspase 3 (Fig. 6A) and fragmented DNA (Fig. 6B). This prevented MSC from osteo-
blastic transformation and calcium deposition (Fig. 6C-E). When MK-2206 was added in parallel, the protective 
effects of Rapa were abolished (Fig. 6A–E).
To test the hypothesis that mTORC2 was the decisive upstream regulator of AKT-dependent anti-calcifying 
cell fate programs induced by Rapa, we performed lentivirus-mediated shRNA knock-down of the 
mTORC2-constituting protein rictor. Lentiviral transfection of MSC with targeted or scrambled shRNA was suc-
cessful as shown by expression of GFP that was also part of the constructs in infected cells (data not shown). 
Rictor protein expression was reduced by 75% after shRNA transfer (Fig. 7A). While mTORC1 signaling was 
not influenced by rictor knock-down (pp70S6KThr389; Fig. 7A), Rapa could no longer induce mTORC2 activa-
tion when rictor was depleted (pAKTSer473; Fig. 7A). As a result, Rapa-induced reduction of cellular senescence 
and apoptotic cell death was not detectable when mTORC2 signaling was restricted (Fig. 7A,B). Furthermore, 
autophagic flux could not be stimulated by Rapa when mTORC2 was deactivated (Fig. 7A). In Rapa-treated MSC 
undergoing osteoblastic differentiation, knock-down of rictor completely antagonized the reduction of ALP activ-
ity (Fig. 7C) and calcium deposition (Fig. 7D,E) observed in MSC with intact rictor expression.
Enhanced mTORC2 signaling is sufficient to protect MSC from calcification. To assess whether 
or not activation of mTORC2 without inhibition of mTORC1 is sufficient to protect MSC from osteoblastic trans-
formation and calcification, we employed lentiviral flag-rictor overexpression during osteoblast differentiation. 
Rictor protein expression was increased 3.5 times after lentiviral transduction (Fig. 8A). Successful infection 
of MSC was also confirmed by detection of flag (Fig. 8A) and GFP (data not shown) that were also part of the 
plasmid. Similar to Rapa, overexpression of rictor resulted in mTORC2 activation as demonstrated by increased 
phosphorylation of AKTSer473 (Fig. 8A). However, in contrast to Rapa-treated cells, mTORC1 signaling was not 
suppressed by rictor overexpression since levels of pp70S6KSer389 were unchanged (Fig. 8A). In comparison 
to Rapa, rictor overexpression had similar effects on cell fates and phenotype: autophagic flux was stimulated 
(Fig. 8A), cellular senescence was prevented (Fig. 8A), anti-apoptotic signaling was increased (Fig. 8A) and cell 
death was reduced (Fig. 8B). Differentiation to calcifying osteoblast-like cells was inhibited as shown by reduced 
Figure 5. Temporal relations of mTORC1 and mTORC2 signaling, cell fates, and phenotypic changes during 
osteoblast differentiation. MSC were cultured for 21 days with osteoblast induction medium and vehicle 
(OM+DMSO), OM and 20 nM Rapa (OM+20 nM Rapa), or OM with 20 nM Rapa and 1 nM bafilomycin A1 
(OM+Rapa+Bafi). (A–C) Representative western blot analyses out of three independent experiments assessing 
activation of downstream targets of the two mTOR complexes (mTORC1: pp70-S6KSer389; mTORC2: pAKTSer473) 
and cell fates (Inhibition of autophagy: LC3B II and p62 with higher levels indicating less degradation due to 
reduced autophagic flux; cellular senescence: p16INK4a) at indicated time points. GAPDH serves as loading 
control. (D) Lactate dehydrogenase (LDH) activity in cell culture supernatants normalized to total protein 
concentrations was determined to quantify cell death. Day 0 was set to 1. (E) Alkaline phosphatase (ALP) 
activity was normalized to total protein concentrations of MSC lysates. (F) Calcium deposition was quantified 
with the ortho-cresolphthalein method and normalized to total protein concentrations. All graphs show 
mean±SEM, n = 5.
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ALP activity (Fig. 8C) and less calcium deposition (Fig. 8D,E). These results suggest that protection from cal-
cific transformation of MSC does not critically rely on mTORC1 inhibition but can be achieved with enhanced 
mTORC2 signaling alone.
Rapa modulates mTOR signaling and activates protective cell fate patterns in vascular cells 
in vivo. As a proof-of-concept, we injected mice with vehicle or low doses of Rapa (1.5 mg/kg) for 37 days 
Figure 6. Pharmacologic inhibition of AKT signaling abrogates the protective Rapa effect on MSC calcification. 
Cells were cultured for 21 days under control conditions, with osteoblast induction medium (OM) and vehicle, 
OM and 20 nM Rapa, or OM with 20 nM Rapa and the total AKT inhibitor MK-2206 (100 nM) as indicated. 
(A) Western blot analyses assessing activation of downstream targets of the two mTOR complexes (mTORC1: 
pp70-S6KSer389; mTORC2: pAKTSer473), inhibition of autophagy (LC3B II, p62), cellular senescence (p16INK4a), 
and apoptosis-related proteins (Bcl-2: negative regulator of apoptosis; cleaved caspase 3 (cl casp 3): executioner 
caspase). Representative western blots from six independent experiments are shown. For densitometric 
quantification, band intensities were normalized to GAPDH as a loading control. Control (no OM) was set to 
1. (B) ELISA for fragmented DNA normalized to total protein concentrations to quantify apoptosis. Control 
was set to 1. (C) Alkaline phosphatase (ALP) activity normalized to total protein concentrations was measured 
after 7 days of incubation. (D) Calcium deposition was quantified with the ortho-cresolphthalein method and 
normalized to total protein concentrations. Bars represent mean + SEM, *P < 0.05, **P < 0.01, ***P < 0.001. 
Numbers of independent experiments are indicated at the bottom of each graph. (E) Alizarin red S staining of 
calcium deposits. Representative experiment out of six, phase contrast microscopy, original magnification x200, 
scale bar = 100 µm.
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and examined local activation levels of mTORC1 and mTORC2 in cells of the aortic wall. By immunofluores-
cence, we found reduced levels of pp70S6K (Fig. 9A) and increased phosphorylation of AKT at Ser473 (Fig. 9B) 
in Rapa-treated animals compared to vehicle-treated controls. pAKTSer473 was detected predominantly in the 
Figure 7. Knock-down of the mTORC2 constituent rictor abrogates the protective Rapa effect on MSC 
calcification. Unspecific control-shRNA (scramble, scr) or shRNA targeting rictor (Ric) were introduced into MSC 
by lentiviral transfer. Cells were cultured for 21 days under control conditions, with osteoblast induction medium 
(OM) and vehicle, or OM and 20 nM Rapa as indicated. (A) Western blot analyses of rictor confirming effective 
knock-down by shRNA, downstream targets of the two mTOR complexes (mTORC1: pp70-S6KSer389; mTORC2: 
pAKTSer473), inhibition of autophagy (LC3B II, p62), cellular senescence (p16INK4a), and apoptosis-related proteins 
(Bcl-2: negative regulator of apoptosis; cleaved caspase 3 (cl casp 3): executioner caspase). Representative western 
blots from six independent experiments are shown. For densitometric quantification, band intensities were 
normalized to GAPDH as a loading control. Control (no OM) was set to 1. (B) ELISA for fragmented DNA 
normalized to total protein concentrations to quantify apoptosis. Control was set to 1. (C) Alkaline phosphatase 
(ALP) activity normalized to total protein concentrations was measured after 7 days of incubation. (D) Calcium 
deposition was quantified with the ortho-cresolphthalein method and normalized to total protein concentrations. 
Bars represent mean + SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Numbers of independent experiments are 
indicated at the bottom of each graph. (E) Alizarin red S staining of calcium deposits. Representative experiment 
out of six, phase contrast microscopy, original magnification x200, scale bar = 100 µm.
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nucleus where it most potently counteracts apoptosis. LC3B II was suppressed showing increased autophagic flux 
(Fig. 9C). Expression of p16INK4a was hardly detectable with Rapa indicating prevention of cellular senescence 
(Fig. 9D). Rapa strongly upregulated anti-apoptotic Bcl-2 (Fig. 9E) and blocked formation of cleaved caspase 3 
Figure 8. Enhanced mTORC2 signaling is sufficient to protect MSC from calcification. Flag-tagged rictor or 
green fluorescent protein (GFP) as a control were introduced into MSC by lentiviral transfer. Cells were cultured 
for 21 days under control conditions, with osteoblast induction medium (OM) and vehicle, or OM and 20 nM 
Rapa as indicated. (A) Western blot analyses of rictor and flag confirming overexpression of rictor due to gene 
transfer, downstream targets of the two mTOR complexes (mTORC1: pp70-S6KSer389; mTORC2: pAKTSer473), 
inhibition of autophagy (LC3B II, p62), cellular senescence (p16INK4a), and apoptosis-related proteins (Bcl-2: 
negative regulator of apoptosis; cleaved caspase 3 (cl casp 3): executioner caspase). Representative western 
blots from six independent experiments are shown. For densitometric quantification, band intensities were 
normalized to GAPDH as a loading control. Control (no OM) was set to 1. (B) Lactate dehydrogenase (LDH) 
activity in cell culture supernatants normalized to total protein concentrations was determined to quantify cell 
death. Control was set to 1. (C) Alkaline phosphatase (ALP) activity normalized to total protein concentrations 
was measured after 7 days of incubation. (D) Calcium deposition was quantified with the ortho-cresolphthalein 
method and normalized to total protein concentrations. Bars represent mean + SEM, *P < 0.05, **P < 0.01, 
***P < 0.001. Numbers of independent experiments are indicated at the bottom of each graph. (E) Alizarin 
red S staining of calcium deposits. Representative experiment out of six, phase contrast microscopy, original 
magnification x200, scale bar = 100 µm.
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(Fig. 9F) as a sign of suppressed apoptosis. Thus, Rapa induced the same mTOR signaling pattern and protective 
cell fate profile in murine vascular cells in vivo as observed in the cell culture model of calcifying human MSC.
Discussion
We identified the major integrator of nutrient status and growth factor signaling, mTOR, as a decisive factor gov-
erning differentiation of human MSC to cells with osteoblast-like functionality. The central role of both mTOR 
complexes, mTORC1 and mTORC2, in the regulation of cell fate programs accounted for their fundamental 
influence on MSC osteoblastic differentiation. Activation of mTORC1 and mTORC2 was observed during oste-
oblastic differentiation and progressive calcification of MSC. This phenotype conversion was linked to blockade 
of autophagy, induction of cellular senescence, and initiation of apoptotic cell death. Pharmacologic intervention 
with Rapa potently prevented osteoblast differentiation and calcification by inhibition of mTORC1 and reciprocal 
activation of mTORC2 associated with alternative cell fate programs: early stimulation of autophagy was evident 
before phenotypic changes occurred followed by reduced cellular senescence and apoptosis. Mechanistically, 
preservation of an undifferentiated state critically depended on enhanced mTORC2 signaling via AKT and 
maintenance of autophagic flux as revealed by pharmacologic and genetic studies. In vivo experiments in mice 
confirmed that protective mTOR signaling and cell fate patterns antagonizing osteoblastic differentiation and 
calcification in vitro can be induced in artery walls by systemic administration of Rapa. We provide a rationale for 
therapeutic mTOR modulation to prevent exhaustion of the regenerating MSC pool and to protect from vascular 
calcification due to age and metabolic diseases. Furthermore, mTOR can be targeted to enhance osteoblastic dif-
ferentiation of MSC in cell therapeutic approaches for degenerative bone diseases and osseous defects.
Degeneration and regeneration depend on cell fate patterns controlled by mTOR. Loss of 
regenerative capacity to maintain the functional reserve of vital organs is a physiologic, age-related phenomenon 
Figure 9. Rapa modulates mTOR signaling and activates protective cell fate patterns in vascular cells in 
vivo. Ten-week-old mice were exposed to Rapa (1.5 mg/kg) or vehicle for 37 days. 4 mice per group were 
studied. Sections from aortas were stained by immunofluorescence for (A) the mTORC1 downstream target 
pp70-S6KThr389, (B) the mTORC2 downstream target pAKTSer473, (C) LC3B with lower levels indicating 
increased degradation due to enhanced autophagic flux, (D) p16INK4a as a marker for cellular senescence, (E) 
Bcl-2, a negative regulator of apoptosis, (F) caspase 3, involved in apoptosis as an executioner caspase. Nuclei 
were counterstained with DAPI. Each panel shows a phase contrast micrograph (PC), DAPI staining alone 
(DAPI, blue fluorescence), the specific antibody staining alone (red fluorescence), and the merged image of a 
representative animal. Original magnification × 400, inserts 5× zoom, scale bar = 100 µm. The graphs show 
the proportion of antibody-positive cells out of 100 counted cells identified by DAPI stained nuclei. The vehicle 
group was set to 1. Bars represent mean + SEM, n = 4, *P < 0.05, **P < 0.01, ***P < 0.001.
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leading to impaired stress resistance16. Individual internal and external risk factors such as genetic background, 
chronic metabolic conditions, and environmental circumstances as well as acute insults can accelerate this pro-
cess16,42,43 and increase risk for diseases and premature death. Modulation of mTOR signaling has been shown to 
increase lifespan both on the single cell and organism level in yeast44, helminths45, flies46 and mammals29,47. As a 
potential mechanism, interference with cell fates controlled by mTOR in response to stress and metabolic cues 
has been discussed48. Autophagy, regulated chiefly by mTORC1, is accorded a central role in the preservation of 
juvenile cell adaptability48,49 since it exercises a double function as a survival mechanism in cellular stress con-
ditions: during starvation, when mTORC1 is physiologically inhibited, autophagy regenerates basal metabolic 
precursors by “self-cannibalism” of cellular structures24. On the other hand, cellular debris such as misfolded pro-
teins and dysfunctional organelles that can induce senescence and apoptosis is cleared by autophagy50. In our cell 
culture model of osteoblastic differentiation of MSC, reduced autophagy was the first detectable cell fate change in 
response to calcifying conditions. Modulation of mTOR signaling with Rapa potently maintained autophagic flux 
as indicated by lower levels of LC3B II and p62 due to lysosomal degradation and effectively ameliorated calcifi-
cation. Conversely, blockade of autophagy with continuous, low-dose administration of bafilomycin A1 resulting 
in accumulation of autophagosomal LC3B II and p62, demonstrating reduced autophagic flux precipitated oste-
oblastic differentiation and calcium deposition. This argues that autophagy can be ascribed a central position in 
the transition from undifferentiated MSC to osteoblast-like calcifying cells.
Cellular senescence and apoptotic cell death followed reduced autophagy later in the time course of MSC dif-
ferentiation to osteoblasts, suggesting that these cell fate changes might be secondary. However, Rapa indirectly 
activated mTORC2 whose downstream target AKT provides anti-apoptotic effects via inhibition of FOXO28. The 
importance of apoptosis for vascular calcification is supported by studies in VSMC demonstrating that apoptotic 
bodies from dying VSMC form a nidus to nucleate apatite41. Furthermore, apoptotic cells are specifically found 
in calcifying areas of arteries from patients with arteriosclerosis51. Thus, resistance to apoptosis by activation of 
survival mechanisms via mTORC2/AKT appears to be another important mechanism contributing to protection 
from calcific transformation of MSC besides enhanced autophagy.
It was reported that Rapa treatment preserved undifferentiated stem cell function and osteogenic differen-
tiation potential during prolonged culture and expansion of MSC in vitro while senescence and DNA damage 
were reduced52. Interestingly both maintenance of fully functional MSC in their stem cell niche and resistance to 
calcifying stimuli rely on cellular functions that are associated with youth and longevity, progressively decrease 
during aging, and can be enhanced by mTOR modulation with Rapa. We propose that age-related arterial calci-
fication and accelerated arteriosclerosis in chronic metabolic diseases share inappropriate function of vascular 
progenitors due to a preponderance of adverse cell fates over regenerative ones. Enabling protective cell fate pat-
terns in the MSC-pericyte-VSMC-continuum could be a novel approach for prevention and treatment of vascular 
diseases.
Harnessing the mTOR network for endogenous and exogenous regenerative approaches. The 
most striking finding of our study is that Rapa-mediated blockade of osteoblastic differentiation and calcification 
was not solely due to inhibition of mTORC1 but crucially depended on enhanced mTORC2 signaling. Rapa is an 
inhibitor of mTORC1 without direct effects on mTORC2. However, depending on cell type, tissue, and duration 
of exposure, Rapa can either indirectly activate or inhibit signaling via mTORC233,40. During osteoblastic differ-
entiation of MSC, Rapa was a potent activator of mTORC2 throughout the whole time course of three weeks. 
Genetic ablation of mTORC2 by targeting its obligatory constituent rictor with shRNA completely abolished 
the differentiation blockade induced by Rapa and pharmacologic inhibition of the mTORC2 downstream target 
AKT had the same effect. Conversely, isolated activation of mTORC2 by rictor overexpression without mTORC1 
inhibition was sufficient to confer protection from calcification. Thus, mTORC2-dependent cell functions are 
essential and appear to be even more important for Rapa-mediated antagonism of differentiation than the coun-
teraction of processes classically controlled by mTORC1 such as ribosomal biogenesis and protein synthesis. Our 
results suggest an as-yet-unknown role for mTORC2 in the preservation of pluripotency in stem and progenitor 
cells.
Activated mTORC1 signaling, as found in MSC in transition to calcifying osteoblasts, is the signature status of 
the mTOR network in conditions with prominent cardiovascular pathologies such as chronic nutrient overload, 
obesity, and diabetes mellitus type 221. Inhibition of mTORC1 with reciprocal activation of mTORC2 has been 
reported to confer protection in cardiovascular diseases. When mTORC2 signaling was induced as a consequence 
of mTORC1 inhibition by either Rapa37 or overexpression of PRAS4053,54, hearts were protected from maladaptive 
hypertrophy and pathologic remodeling as well as from cardiomyocyte apoptosis. Rapa attenuated atherosclero-
sis in apolipoprotein E-deficient mice55 and vascular calcification in rats with chronic renal failure56. In a recent 
study, Rapa reduced aortic calcium load and prolonged survival in a mouse model for uremic vascular media cal-
cification57. Notably, Rapa mediated protection was associated with induction of autophagy in aortic walls57. Our 
findings provide a mechanistic explanation for these observations, since we demonstrated that systemic adminis-
tration of Rapa shifts mTOR signaling in favor of mTORC2 while suppressing mTORC1 in vascular cells in vivo. 
Similar to Rapa-treated MSC undergoing osteoblastic differentiation in vitro, autophagy was stimulated while 
senescence and apoptosis were reduced in vascular cells of Rapa-treated mice, implicating protection against 
arterial calcification through enhanced mTORC2 signaling.
Nevertheless, therapeutic interventions in patients aimed at reducing mTORC1 activity and increas-
ing mTORC2 activity are hampered by several considerations. Rapa and similar mTORC1 inhibitors already 
approved for clinical use can also block instead of activate mTORC2 in some cells and settings with detrimental 
effects. As an example, transplanted patients receiving Rapa as an immunosuppressant can develop focal seg-
mental glomerulosclerosis due to podocyte injury associated with reduced mTORC2 function58. In addition, the 
reciprocal activation of mTORC2 upon mTORC1 blockade by Rapa might be different in women and men since 
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mouse hearts challenged by mineralocorticoid excess showed a sexual dimorphism in this regard37 and the pos-
itive effect of Rapa on lifespan in mice was greater in females than in males47. However, we included MSC from 
women and men in our study and did not observe any significant interaction between sex and the response to 
Rapa. Finally, activation of mTORC2 may have adverse effects such as facilitation of tumor growth due to reduced 
susceptibility to physiologic apoptotic stimuli. Alternatively, exogenous regenerative strategies might be advanta-
geous because they offer the opportunity for selective intervention in a specific cell type ex vivo.
Autologous and allogenic MSC hold great potential for cell therapeutic treatment of hard-to-heal osseous 
lesions either due to developmental defects in pediatric patients or to osteoporotic fractures in the elderly. In 
accordance to our study, a biphasic approach could yield optimal results: During culture and expansion of MSC 
previous to implantation, activation of mTORC2 might preserve stemness and their functionality as progen-
itors, whereas activation of mTORC1 and simultaneous inhibition of mTORC2 in the differentiation phase 
might enhance osteoblastic output and improve calcification. During the expansion phase, selective activation 
of mTORC2 with novel pharmacologic or genetic methods seems advantageous over mTOR modulation with 
conventional mTORC1 inhibitors such as Rapa since mTORC1 blockade has profound anti-proliferative effects.
Limitations. The use of bone marrow-derived cells to study vascular calcification could be questioned. 
Our aim was to specifically address progenitor cells to enhance endogenous regeneration as a more promising 
approach as compared to targeting terminally differentiated cells. Pericytes, the local progenitors to vascular 
smooth muscle cells, are very hard to isolate in sufficient numbers. Thus, we chose to study bone marrow-derived 
MSC that circulate and replenish pericytes in the vasculature2,59,60. This relationship and the reported similarities 
of pericytes and MSC59 give confidence that the same mechanisms are operative in both, pericytes located in the 
vessel wall and bone marrow derived MSC as their systemically circulating counterparts. Furthermore, MSC can 
easily be isolated from bone marrow aspirates, allowing for standardized experiments with MSC from multiple 
donors to account for inter-individual variation.
Although protein levels of the key subunits of mTORC1 and mTORC2, raptor and rictor, were not affected 
in osteoblast differentiation or by Rapa treatment, formation of one or both complexes might have changed. 
For example, recruitment of rictor to mTOR might be enhanced by Rapa resulting in increased formation of 
mTORC2 and phosphorylation of AKT at serine 473 despite unchanged protein levels. However, prolonged treat-
ment with Rapa has been reported to inhibit formation of mTORC2 under certain conditions33. Investigations of 
protein-protein-interactions were beyond the scope of the present study.
Bafilomycin A1 blocks autophagy by inhibition of the V-ATPase preventing acidification of lysosomes and by 
blockade of autophagosome-lysosome fusion. Furthermore, bafilomycin A1 can act as a potassium ionophore61. 
Although various cell types may have different sensitivities to ionophoric activities and bafilomycin A1 has a 
rather low affinity for potassium ions62 we cannot verify that the effects of bafilomycin A1 in our study were solely 
related to inhibition of autophagy and not to its ionophoric action.
We did not validate our findings in an in vivo model for vascular calcification. However, Rapa induced exactly 
the same signaling patterns and effects on cell fates in vascular cells in vivo as we observed in our in vitro model. 
These findings confirm the concept of induction of regenerative cell fate patterns in vascular cells by activation of 
mTORC2. This novel therapeutic intervention could be beneficial in several vascular pathologies beyond vascular 
calcification and should therefore be tested in various in vivo models of vascular damage in the future.
Conclusion
The bone-vascular axis is controlled by endocrine and metabolic signals impinging on the mTOR network and is 
progressively dysfunctional with aging and in chronic diseases, leading to loss of bone mass while vascular calci-
fication progresses. MSC, capable of osteoblastic differentiation and calcification, have a dual role as progenitors 
to osteoblasts and as pericytes to VSMC. We found that degenerative cell fates associated with both, aging and 
metabolic diseases such as cellular senescence and apoptosis were activated during osteoblast differentiation of 
MSC while autophagy as a protective mechanism was reduced. Concomitant treatment with Rapa “rejuvenated” 
MSC by inducing autophagy and reducing cellular senescence and apoptosis via inhibition of mTORC1 and 
simultaneous activation of mTORC2 resulting in potent reduction of osteoblastic differentiation and calcification. 
We propose that therapeutic interventions aimed at the preservation of the regenerative capacity of vascular pro-
genitor cells is most promising for the prevention of chronically progressing conditions such as arteriosclerosis 
as well as for the treatment of already established vascular lesions by enabling endogenous regeneration. Our 
study identified mTORC2, a thus far scarcely studied part of the mTOR network, as a powerful molecular target 
for maintenance of an undifferentiated state in MSC. Targeted interventions, particularly in the elderly and in 
patients with chronic metabolic diseases, may help restore a functional bone-vascular axis to reduce ectopic 
osteoblastic differentiation of MSC leading to prevention of osteoporotic fractures and improved vascular health.
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